By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Aria Diagnostics said today that it has begun a blinded, multicenter clinical trial that will compare its non-invasive prenatal trisomy 21 screening test with standard screening methods.

The company's test, which is still in development, is based on a sequencing-based method that analyzes cell-free DNA in maternal blood to detect fetal chromosomal abnormalities.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: mouse genome functional analysis, more sensitive chromatin immunoprecipitation, and more.

The Center for Data Innovation and HealthITNow argue for re-building of genomic research infrastructure.

A Senate committee has unanimously approved a bill to require articles resulting from federally funded projects to be made publicly available, according to ScienceInsider.

The US is heading toward another budget showdown, Nature News says.